John Matthew Collins - 27 Oct 2023 Form 4 Insider Report for CALIX, INC (CALX)

Role
Chief Commercial Ops Officer
Signature
/s/ Tom Gemetti as Attorney-in-Fact for John Matthew Collins
Issuer symbol
CALX
Transactions as of
27 Oct 2023
Net transactions value
-$1,488,900
Form type
4
Filing time
30 Oct 2023, 17:02:28 UTC
Previous filing
26 Jul 2023
Next filing
12 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALX Common Stock Options Exercise $104,250 +15,000 $6.95* 15,000 27 Oct 2023 Direct
transaction CALX Common Stock Options Exercise $120,450 +15,000 +100% $8.03* 30,000 27 Oct 2023 Direct
transaction CALX Common Stock Options Exercise $274,800 +30,000 +100% $9.16* 60,000 27 Oct 2023 Direct
transaction CALX Common Stock Sale $1,988,400 -60,000 -100% $33.14 0 27 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALX Stock Option (right to buy) Options Exercise $0 -15,000 -43% $0.000000 20,171 27 Oct 2023 Common Stock 15,000 $6.95 Direct F2
transaction CALX Stock Option (right to buy) Options Exercise $0 -15,000 -38% $0.000000 25,000 27 Oct 2023 Common Stock 15,000 $8.03 Direct F3
transaction CALX Stock Option (right to buy) Options Exercise $0 -30,000 -15% $0.000000 165,000 27 Oct 2023 Common Stock 30,000 $9.16 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold between $32.39 and $34.12 per share at a weighted average price of $33.14. The reporting person will provide full information regarding the number of shares sold at each sale price upon request.
F2 80,000 of the shares subject to the option grant were fully vested and exercisable on July 17, 2021.
F3 45,000 of the shares subject to the option grant were fully vested and exercisable on February 14, 2023.
F4 175,000 of the shares subject to the option grant were fully vested and exercisable on July 31, 2023.